SARS-CoV-2 Spike Protein RBD (Omicron B.1.1.529 Variant) Neutralizing Antibody

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Protein RBD (Omicron B.1.1.529 Variant) Neutralizing Antibody is a recombinant Human Monoclonal Antibody expressed in CHO cells against SARS-CoV-2/COVID-19 Spike Protein RBD (Omicron B.1.1.529 Variant).

The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the S1 and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.
The B.1.1.529 (Omicron) variant was identified in South Africa in November 2021. It possess a large number of mutations which appear to increase the risk of reinfection compared to other variants of concern.
Supplier Abbexa Ltd.
Product # abx376490-1MG
Pricing 1 mg USD $1725.5
Clonality Monoclonal
Conjugation Unconjugated
Host Human
Tested Applications ELISA, WB
Dry Ice No
Availability Shipped within 5-12 working days.
Note This product is for research use only.
Feedback